LCNDG Rapid Review: Bortezomib for first-line, transplant unsuitable multiple myeloma

Source: London Cancer New Drugs Group Area: Evidence > Drug Specific Reviews There are no trials directly comparing bortezomib, melphalan, and prednisolone versus thalidomide-based regimens in patients with multiple myeloma who are not able to receive high-dose therapy and stem cell transplant.   The phase III open-label randomised control trial investigating melphalan-prednisolone (control arm) against bortezomib-melphalan-prednisolone (bortezomib arm) reported a median time to progression of 24 months in the bortezomib arm and 16.6 months in the control arm (hazard ratio 0.48; P<0.001). The response could be evaluated in 337 patients in the bortezomib arm and 331 in the control arm. The rates of partial response or better were 71% in the bortezomib arm and 35% in the control arm (P<0.001), and the complete response rates were 30% and 4%, respectively (P<0.001). The median duration of response was 19.9 months in the bortezomib arm and 13.1 months in the control arm; the median duration of response among patients who had a complete ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news